<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; Vaccines</title>
	<atom:link href="http://pharmaexecnews.com/category/fda/vaccines-fda/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Nasal Spray Vaccines More Effective against Flu</title>
		<link>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/</link>
		<comments>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11485</guid>
		<description><![CDATA[New research has shown that nasal vaccines are much more effective in providing protection against the flu. In fact the research also proved that nasal vaccines will soon protect not only against the flu and pneumonia, but also against bioterrorism agents such as Yersinia pestis that causes the plague. The research, presented at the Society [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Completes $125M Acquisition of Tianyuan</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/#comments</comments>
		<pubDate>Fri, 25 Mar 2011 14:00:27 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11369</guid>
		<description><![CDATA[Novartis has completed its acquisition of 85% in the Chinese vaccines firm Zhejiang Tianyuan Bio-Pharmaceutical. The deal, roughly valued at $125 million, was first announced in November 2009. Swiss drugs giant Novartis has said that the acquisition will provide it with an expanded presence in the Chinese vaccines market and also facilitate the introduction of [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Now – Nanoparticles for Long Lasting Immunity</title>
		<link>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/</link>
		<comments>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/#comments</comments>
		<pubDate>Tue, 15 Mar 2011 08:00:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[nano]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[nanotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11290</guid>
		<description><![CDATA[Every vaccine scientist wants to discover just one thing – how to stimulate immunity that lasts for a lifetime! There are many live vaccines, such as the ones for smallpox and yellow fever that are able to stimulate immunity against the disease that lasts for many decades. However, in spite of the success of such [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Inhalable Measles Vaccine Tested</title>
		<link>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/</link>
		<comments>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 08:00:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11197</guid>
		<description><![CDATA[Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine, measles remains an important killer of children worldwide, particularly in less-developed regions where vaccination coverage is limited. A team of researchers, led by scientists at the Johns Hopkins Bloomberg School of Public Health and the University of Colorado, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Researchers &#8216;Unzip&#8217; MRSA&#8217;s Armor for Possible Vaccine</title>
		<link>http://pharmaexecnews.com/biotechnology/researchers-unzip-mrsas-armor-vaccine/</link>
		<comments>http://pharmaexecnews.com/biotechnology/researchers-unzip-mrsas-armor-vaccine/#comments</comments>
		<pubDate>Mon, 24 Jan 2011 08:00:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11099</guid>
		<description><![CDATA[MRSA (methicillin-resistant staphylococcus aureus) is one tough nut to crack. Researchers have failed to produce a vaccine because agents cannot break through the life-threatening bacteria&#8217;s armor. So, while other research has targeted the surface of the bacteria, a team from the University of Rochester Medical Center has discovered an antibody that reaches beyond the microbe&#8217;s [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/researchers-unzip-mrsas-armor-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK Malaria Vax Shows Promising Results</title>
		<link>http://pharmaexecnews.com/biotechnology/gsk-malaria-vax-shows-promising-results/</link>
		<comments>http://pharmaexecnews.com/biotechnology/gsk-malaria-vax-shows-promising-results/#comments</comments>
		<pubDate>Wed, 19 Jan 2011 08:00:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11085</guid>
		<description><![CDATA[Mosquirix, an experimental malaria vaccine from GlaxoSmithKline, provides African children with long-lasting protection and reduces the risk of infection by the parasite that causes severe malaria by 46 percent over 15 months, according to researchers.

Between March 2007 and October 2008, the researchers enrolled healthy children between the ages of 5-17 months in Kenya and Tanzania. [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/gsk-malaria-vax-shows-promising-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>H1N1 Vaccine Linked to 700% Increase in Miscarriages?</title>
		<link>http://pharmaexecnews.com/biotechnology/h1n1-vaccine-linked-700-increase-miscarriages/</link>
		<comments>http://pharmaexecnews.com/biotechnology/h1n1-vaccine-linked-700-increase-miscarriages/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 08:00:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10966</guid>
		<description><![CDATA[Recent data presented to the U.S. Centers for Disease Control and Prevention&#8217;s (CDC) Advisory Committee on Children&#8217;s Vaccines has revealed some shocking information about the effects of the H1N1 / swine flu vaccine on pregnant women. According to the National Coalition of Organized Women, the rate of miscarriage among pregnant women during the 2009 H1N1 [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/h1n1-vaccine-linked-700-increase-miscarriages/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Experts Urge U.S. to Start Stockpiling Cholera Vaccine</title>
		<link>http://pharmaexecnews.com/biotechnology/experts-urge-start-stockpiling-cholera-vaccine/</link>
		<comments>http://pharmaexecnews.com/biotechnology/experts-urge-start-stockpiling-cholera-vaccine/#comments</comments>
		<pubDate>Fri, 10 Dec 2010 08:00:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10962</guid>
		<description><![CDATA[As some project that Haiti will be hit with another 200,000 cholera infections in the next three months, experts from Harvard Medical School, George Washington University and the International Vaccine Institute are urging the U.S. to stockpile cholera vaccines. According to the experts, who wrote a perspective article in the New England Journal of Medicine, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/experts-urge-start-stockpiling-cholera-vaccine/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Higher Income Parents Forgoing Kids&#8217; Vaccinations</title>
		<link>http://pharmaexecnews.com/biotechnology/higher-income-parents-forgoing-kids-vaccinations/</link>
		<comments>http://pharmaexecnews.com/biotechnology/higher-income-parents-forgoing-kids-vaccinations/#comments</comments>
		<pubDate>Mon, 08 Nov 2010 08:00:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10884</guid>
		<description><![CDATA[Vaccination rates for children insured by commercial plans declined roughly four percentage points between 2008 and 2009. And experts fear that if this trend continues, the public&#8217;s health could be jeopardized.  &#8221;Rates had been gradually improving in the commercial plans. This was the first time we&#8217;d seen a drop&#8211;and it was a pretty big drop,&#8221; [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/higher-income-parents-forgoing-kids-vaccinations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Charity Funds Brain Cancer Vaccine Trial</title>
		<link>http://pharmaexecnews.com/biotechnology/charity-funds-brain-cancer-vaccine-trial/</link>
		<comments>http://pharmaexecnews.com/biotechnology/charity-funds-brain-cancer-vaccine-trial/#comments</comments>
		<pubDate>Fri, 05 Nov 2010 08:00:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10859</guid>
		<description><![CDATA[Cancer Research UK is set to begin a Phase I trial for glioblastoma, a deadly form of brain cancer. Forty-five patients have been recruited to receive the vaccine IMA950. The drug contains 11 peptides that are found in tumors but not healthy tissue. They &#8220;train&#8221; T cells in the immune system to recognize cancer cells [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/charity-funds-brain-cancer-vaccine-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

